Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

Study Finds Higher Rates of Leukemia in 9/11 Responders and Recovery Workers

Investigators  discovered an increase in the incidence of leukemia in first responders and other recovery workers who were at the World Trade Center (WTC)...

Acalabrutinib Approved for CLL Under New International Collaboration

The FDA granted a supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Acalabrutinib...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Time-Limited Acalabrutinib Combination Has “Encouraging” Response Rates in Previously Untreated Chronic Lymphocytic Leukemia

Watch our interview with Benjamin Lampson, MD. Preliminary results from a trial presented at the 2019 ASH Annual Meeting suggest that time-limited frontline therapy for...

Zanubrutinib Active in Patients with Treatment-Naive Del17p CLL/SLL

Approximately 93% of patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and del17p responded to treatment with the next-generation Bruton tyrosine kinase...

Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL

Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...

Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL

Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL

The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...

Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve CLL

Acalabrutinib, alone or combined with obinutuzumab, led to greater improvements in progression-free survival (PFS), compared with obinutuzumab plus chlorambucil, in patients with treatment-naïve chronic...
You Make the Call

How would you treat a patient with CLL who developed warm autoimmune hemolytic anemia?

This month, Dr. Jacobsen discusses how to treat a patient with chronic lymphocytic leukemia who develops warm autoimmune hemolytic anemia. And don't forget to check...
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.